Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience.

Background/aims: Alcoholic cirrhosis, smoking, and use of calcineurin inhibitors (CNI) are associated with the development of de novo tumors in liver transplant (LT) recipients. Sirolimus is an immunosuppressor with antitumoral properties.

Methodology: Between April 1986 and April 2007, we performed 1231 liver transplants in 1084 recipients.